Institution
Children's Memorial Hospital
Healthcare•
About: Children's Memorial Hospital is a based out in . It is known for research contribution in the topics: Population & Transplantation. The organization has 5652 authors who have published 8967 publications receiving 283837 citations.
Topics: Population, Transplantation, Medicine, Poison control, Health care
Papers published on a yearly basis
Papers
More filters
••
Cincinnati Children's Hospital Medical Center1, Wayne State University2, University of Miami3, Boston Children's Hospital4, Children's Memorial Hospital5, University of Alberta6, Primary Children's Hospital7, Monroe Carell Jr. Children's Hospital at Vanderbilt8, Children's Hospital of Philadelphia9, St. Louis Children's Hospital10, Morgan Stanley Children's Hospital11, University of Tennessee Health Science Center12
TL;DR: The specific LVNC-associated cardiomyopathy phenotype predicts the risk of death or transplantation and should inform clinical management.
131 citations
••
TL;DR: It is concluded from the experience that liver transplantation can be an effective treatment for children with urea cycle defects and whether the quality of life is improved and medical expense is reduced by transplantation.
Abstract: The principal goal of therapy when liver transplantation is used for the treatment of metabolic disease is to correct the metabolic error. By doing so, liver transplantation eliminates the hepatic and peripheral consequences of the error. Inborn errors involving the urea cycle appear on theoretical grounds to be amenable to treatment using liver transplantation and, indeed, published data demonstrate that this approach to therapy can be successful. The purpose of this study is to examine the outcome of liver transplantation done for the indication of urea cycle defects in a large group of patients. The first goal of the study is to determine with certainty that liver transplantation corrects hyperammonaemia and halts the progress of disease. A second goal is to determine the extent of neurological recovery in children previously injured by hyperammonaemia. The final goal is to understand whether the quality of life is improved and medical expense is reduced by transplantation. The study involved a survey of major transplantation centres. Four centres provided data about 16 patients, 14 of whom were alive 11 months to 6 years after transplantation. The results demonstrate that liver transplantation resulted in correction of hyperammonaemia in all patients. The neurological outcome after transplantation correlated closely with the condition prior to transplantation. This population of patients has had relatively few problems in the long term related to the liver transplant itself. The quality of life seems to be much improved, but further study will be needed to confirm this. Limited data involving two patients show a reduction in the cost of care. We conclude from our experience that liver transplantation can be an effective treatment for children with urea cycle defects.
131 citations
••
Children's Hospital of Philadelphia1, University of Michigan2, Johns Hopkins University3, Boston Children's Hospital4, University of California, San Francisco5, Mount Sinai Hospital6, Northwestern University7, Washington University in St. Louis8, Children's Memorial Hospital9, University of Colorado Denver10
TL;DR: The BARC histologic assessment system diagnosed BA with a high level of sensitivity and identified infants with biliary obstruction with reasonable interobserver agreement, however, distinguishing between BA and disorders such as total parenteral nutrition-associated liver disease and alpha(1)-antitrypsin deficiency is not possible without adequate clinical information.
131 citations
••
TL;DR: The Pediatric AIDS Clinical Trials Group 338, a multicenter, phase 2, randomized, open-label controlled trial conducted from February 6 to April 30, 1997 (patient entry period); patients were followed up for 48 weeks as discussed by the authors.
Abstract: ContextAlthough protease inhibitors are used routinely in adults with human
immunodeficiency virus (HIV) infection, the role of these drugs in the treatment
of clinically stable HIV-infected children is not clear.ObjectiveTo evaluate the safety, tolerance, and virologic response produced by
a change in antiretroviral therapy in HIV-infected children who were clinically
and immunologically stable while receiving previous therapy.DesignThe Pediatric AIDS Clinical Trials Group 338, a multicenter, phase 2,
randomized, open-label controlled trial conducted from February 6 to April
30, 1997 (patient entry period); patients were followed up for 48 weeks.SettingPediatric HIV research clinics in the United States and Puerto Rico.PatientsTwo hundred ninety-seven antiretroviral-experienced, protease inhibitor–naive,
clinically stable HIV-infected children aged 2 to 17 years.InterventionsChildren were randomized to receive zidovudine, 160 mg/m2
3 times per day, plus lamivudine, 4 mg/kg 2 times per day (n = 100); the same
regimen plus ritonavir, 350 mg/m2 2 times per day (n = 100); or
ritonavir, 350 mg/m2 2 times per day, and stavudine, 4 mg/kg 2
times per day (n = 97).Main Outcome MeasurePlasma HIV-1 RNA levels at study weeks 12 and 48, compared among the
3 treatment groups.ResultsAt study week 12, 12% of patients in the zidovudine-lamivudine group
had undetectable plasma HIV RNA levels (<400 copies/mL) compared with 52%
and 54% of patients in the 2- and 3-drug ritonavir-containing groups, respectively
(P<.001). Through study week 48, 70% of children
continued receiving their ritonavir-containing regimen. At study week 48,
42% of children receiving ritonavir plus 2 nucleosides compared with 27% of
those receiving ritonavir and a single nucleoside had undetectable HIV RNA
levels (P = .04); however, similar proportions in
each group continuing initial therapy had HIV RNA levels of less than 10,000
copies/mL (58% vs 48%, respectively; P = .19).ConclusionsIn our study, change in antiretroviral therapy to a ritonavir-containing
regimen was associated with superior virologic response at study week 12 compared
with change to a dual nucleoside analog regimen. More children receiving ritonavir
in combination with 2 compared with 1 nucleoside analog had undetectable HIV
RNA levels at study week 48.
130 citations
••
TL;DR: The recent advances in basic research and clinical progress in these diseases are reviewed, as well as the research needs, and current key questions and controversies are formulated and top priorities to guide future research are identified.
130 citations
Authors
Showing all 5672 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jorge E. Cortes | 163 | 2784 | 124154 |
Marc C. Hochberg | 127 | 691 | 87268 |
Michael Andreeff | 117 | 959 | 54734 |
Bharat Bhushan | 116 | 1276 | 62506 |
Donald M. Lloyd-Jones | 115 | 706 | 112655 |
David N. Herndon | 108 | 1227 | 54888 |
Frederick J. Schoen | 102 | 434 | 42611 |
Kathryn M. Edwards | 102 | 628 | 39467 |
Alan R. Dyer | 95 | 283 | 44252 |
Mark C. Willingham | 94 | 394 | 36167 |
Nicholas Katsanis | 93 | 348 | 34133 |
Peter D. Gluckman | 92 | 525 | 33375 |
Helga Refsum | 90 | 316 | 37463 |
Dale A. Schoeller | 90 | 391 | 30776 |
Shlomo Shinnar | 90 | 288 | 25621 |